Purpose: The vesicular acetylcholine transporter (VAChT) is a specific biomarker for imaging presynaptic cholinergic neurons. Herein, two potent and selective 11 C-labeled VAChT inhibitors were evaluated in rodents and nonhuman primates for imaging VAChT in vivo. 
Introduction
T he vesicular acetylcholine transporter (VAChT), predominantly located in the presynaptic vesicles [1] [2] [3] , is responsible for the loading of acetylcholine (ACh) into presynaptic vesicles. This has been demonstrated by noncompetitive inhibition of ACh storage when VAChT is bound to trans-2-(4-phenylpiperidino)cyclohexanol (vesamicol) [4, 5] ; vesamicol binds to VAChT at a site different from the acetylcholine transporter recognition site. Extensive research has revealed that VAChT plays a vital role in the release of ACh and physiological functions in the central nervous system and is highly expressed in the striatum [6] . VAChT is widely accepted as a reliable biomarker for the abnormal cholinergic function, which is associated with the severity of dementia and other neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease [7] [8] [9] .
Positron emission tomography (PET) is a noninvasive imaging modality that can be used to quantify VAChT in vivo and study changes in cholinergic function in response to therapy; it is widely applied in the clinical investigation of central nervous system disorders and other diseases [10] [11] [12] [13] [14] . In the companion manuscript [15] , we reported the synthesis and radiosynthesis of two potent and selective 11 
C-labeled VAChT inhibitors, (−)-[ 11 C]2 and (−)-[
11 C]6 ( Fig. 1) . Here, we reported the in vitro characterization of the binding affinity of these compounds and the in vivo evaluation of the two radioligands in rodents and nonhuman primates (NHPs).
Methods

In Vitro Biological Evaluation
VAChT Binding Affinity Studies The binding affinity for both enantiomers of each of the two new compounds was determined using in vitro competition assays with [ 3 H]vesamicol at a subsaturating concentration of 5 nM for binding to human VAChT present in synaptic-like microvesicles in postnuclear supernatant prepared from PC12 A123.7 cells [16] . As in our previous studies of VAChT inhibitors, nonspecific binding was determined from samples that contained 1 μM of nonradioactive (±)-vesamicol and test compounds were assayed in increments of 10-fold from 0.1 to 10,000 nM concentration [5, [17] [18] [19] [20] . The surfaces of containers were precoated with Sigmacote (Sigma-Aldrich, MO). Samples containing 200 μg postnuclear supernatant in 200 μl of 110 mM potassium tartrate, 20 mM HEPES (pH 7.4 with KOH), 1 mM dithiothreitol, and 0.02 % sodium azide were incubated at 22°C for 24 h. A volume of 90 μl was filtered in duplicate through GF/F glass fiber filters coated with polyethylenimine and washed. Filter-bound radioactivity was determined by liquid scintillation spectrometry for 10 min per sample. Averaged data were fit by regression analysis with a rectangular hyperbola to estimate K i . All compounds were independently assayed at least twice.
Sigma Receptor Binding Affinity Study The σ receptor binding studies were conducted as previously reported [21, 22] . The σ 1 receptor binding assays were performed in 96-well plates using approximately 300 μg protein of guinea pig brain membrane homogenate and 5 nM (+)- [ 3 H]pentazocine (1.30 GBq/μmol, PerkinElmer, Boston, MA); nonspecific binding was determined from samples that contained 10 μM of cold haloperidol. The σ 2 receptor binding assays were similarly performed using rat liver membrane homogenates (∼300 μg protein) and ∼5 nM [ 3 H]ditolylguanidine (2.15 GBq/μmol, PerkinElmer, Boston, MA) in the presence of 1 μM (+)-pentazocine to block σ 1 sites; nonspecific binding was determined from samples that contained 10 μM of cold haloperidol. Data from these experiments were modeled using nonlinear regression analysis to determine the concentration that inhibits 50 % of the specific binding of the radioligand (IC 50 value). Competitive binding curves were best fit to a one-site model and gave pseudo-Hill coefficients of 0.6-1.0. K i values were calculated using the method of Cheng and Prusoff [23] and are presented as the mean±SEM. A K i value of 7.89 nM for (+) , the rats were again anesthetized and euthanized. In addition to these baseline studies, the specific uptake of (−)-[ 11 C]2 was evaluated at 30 min p.i. using (±)-2 to block VAChT and YUN-143 to block σ 1/2 receptors in the brain; blocking agents were injected 2 min before the radiotracer. The whole brain was quickly harvested, the blood was removed by blotting, and regions consisting of the cerebellum, brain stem, thalamus, striatum, cortex, and hippocampus were separated; the remainder of the brain was collected to determine total brain uptake. Peripheral organs and tissues including blood, lung, liver, kidney, muscle, fat and heart, pancreas, and spleen were also collected; all samples were weighed and counted in an automated well counter with a standard dilution of the injectate. Counts were decay-corrected and the %ID/g calculated. The striatum to organ ratios were calculated by dividing the %ID/g of the striatum by the %ID/g of the nontarget brain region. A two-tailed paired Student's t test was used to compare striatal uptake (%ID/g) in rats pretreated with the blocking agents versus that of control rats. A p value of 0.05 was considered statistically significant. For the ex vivo autoradiography study, a mature male SD rat was injected with 115 MBq of (−)-[ 11 C]2 and euthanized 30 min p.i. as described above. The whole brain was quickly removed and snap-frozen, and 1-mm coronal sections were obtained using a chrome brain matrix (Zivic Instruments Inc., Pittsburg, PA). The brain slices were carefully placed on a clear sheet, covered with film, and counted on an InstantImager (Packard Instrument Company, Meriden, CT). A photographic image was obtained using a flatbed scanner. Acetylcholine esterase (AChE) staining was performed to confirm striatal distribution of VAChT. The whole brain of a mature male SD rat was snap-frozen, and 20-μm sections obtained using a cryotome were thaw mounted onto glass slides and air-dried. Slides were preincubated in 100 mM s o d i u m a c e t a t e b u f f e r , p H 5 . 2 , w i t h 2 0 m M tetra(monoisopropyl)pyrophosphortetramide (iso-OMPA) for 15 min [24] , then transferred into the AChE incubation media (4 mM acetylthiocholine iodide (ASChI), 2 mM copper, 10 mM glycine, and 20 mM iso-OMPA in acetate buffer) for 1 h at 37°C with constant agitation and rinsed three times with deionized water, each for 1 min. Slides were immediately postincubated for 15 min in 3 % potassium ferricyanide in acetate buffer and again rinsed as described above. Finally, the stained sections were dehydrated and covered with a cover slip for digital photomicrography.
The in vivo metabolism of (−)- male SD rats which were euthanized at 5, 20, 40, and 60 min p.i. HPLC metabolite analysis was performed using solvent extracts of plasma samples and brain homogenates from each rat. For blood metabolite analysis, a 1 ml aliquot of heparinized whole blood was centrifuged to separate plasma from packed red cells; 0.4 ml plasma was extracted and deproteinated with 0.6 ml acetonitrile. This 1.0 ml solvent extract of plasma was centrifuged to precipitate the plasma proteins, and 0.2 ml of the supernatant was diluted with 0.2 ml of distilled water for HPLC analysis. The HPLC was equipped with a 200 μl injection loop and an Agilent SB-C18 analytical column (250×4.6 mm, 5 μm); the mobile phase was 37 % acetonitrile/0.1 M ammonium formate buffer (v/v) (pH 4.5), flow rate 1.1 ml/min, and fractions were collected every minute for 16 min. The retention time of the parent compound was 10 min. HPLC fractions were counted in a well counter, and the counts were decay-corrected. For rat brain metabolite analysis, the whole brain was harvested; excess blood was blotted, the tissue was homogenized on ice, and the radioactivity was extracted by adding 1.2 ml of acetonitrile and homogenizing further. A 1.0 ml aliquot of this brain homogenate was centrifuged to pellet the debris; 0.2 ml of the clear supernatant was diluted with 0.2 ml of distilled water for HPLC injection as described above.
In Vivo MicroPET Imaging of the Male Cynomolgus Monkey Brain
For each study, a 2-h dynamic scan was performed on an adult male cynomolgus macaque (3.5-5 kg); three independent microPET scans were conducted on the same subject to make sure the reproducibility of the data. The scanner used for these studies is a microPET Focus 220 scanner (Concorde/CTI/Siemens Microsystems, Knoxville, TN). A detailed description of the procedures used for similar studies has been previously published [25] . After transportation to the PET scanner suite under ketamine anesthesia, the subject was intubated and a percutaneous venous catheter was placed for radiotracer injection. Anesthesia was maintained at 0.75-2.0 % isoflurane/oxygen throughout the PET scanning procedure. The subject was placed supine on the scanner bed, with the brain in the center of the field of view (FOV). Prior to each microPET scanning session, a brief transmission scan was used to check positioning; after confirmation that the target regions were within the FOV, a 45-min transmission scan was obtained for attenuation correction. Subsequently, 340-480 MBq of (−)-[ 11 C]2 was administered via the venous catheter; the PET data acquisition protocol is described below.
MicroPET Image Processing and Analysis
PET scans were collected for 120 min beginning with tracer injection and binned to the following time frames: 3× 1, 4× 2, 3 × 3, and 20 × 5 min. Emission data were corrected for attenuation, scatter, random data, and dead time. PET image reconstructed resolution was G2.0 mm full width half maximum for all three dimensions at the center of the FOV. Correction for movement of individual frames was unnecessary because the anesthetized animal's head was immobilized. An MR image was co-registered to the PET scan using automatic image registration [26] . 3D regions of interest (ROIs) were manually drawn through all planes of co-registered MR images for the striatum and cerebellum. The ROIs were then overlaid on all reconstructed PET images to obtain time-activity curves. Activity measures were standardized to body weight and dose of radioactivity injected to yield the standardized uptake value (SUV).
Results and Discussion
In Vitro Binding Affinity Studies
In vitro binding affinity studies were performed to measure the affinities of 2 and 6 towards the VAChT and sigma (σ) receptors (Table 1) . 
Biodistribution Studies in Rats
Biodistribution in peripheral tissues and regional brain distribution studies of (−)- the results are shown in Table 2 . Rapid initial uptake was observed for both compounds in all organs. For (−)-[ 11 C]2, at 2 min p.i., the uptake in total brain was 0.56 %ID/g. Washout by 30 min p.i. was evident and total brain decreased to 0.34 %ID/g; this trend continued at 60 min p.i. Although the initial blood uptake at 2 min was higher than that in the brain, by 30 min p.i., the %ID/g values of 0.25 for blood and 0.34 for brain suggest that the tracer was cleared from the blood but was retained in the brain. For (−)-[ 11 C]2, for the peripheral tissues, liver had the highest uptake. The regional brain distribution studies of (−)-[ 11 C]2 in rats showed the highest and homogeneous uptake at 2 min p.i. with %ID/g values of 0.57 for the cerebellum, brain stem, and thalamus, and 0.56, 0.58, and 0.51 for the striatum, cortex, and hippocampus, respectively (Fig. 2) . In subsequent time points, retention was the highest in the striatum for (−)- i. in the cerebellum, brain stem, thalamus, cortex, and hippocampus, respectively. These results are consistent with the reported distribution of VAChT in the rat brain, in which striatal tissue is VAChT enriched. Washout was rapid in the cerebellum, the accepted nontarget brain region for VAChT. The uptake ratios in the striatum versus the cerebellum increased significantly over time, from unity at 2 min to 2.4-fold at 60 min p.i. The pyridine tracer (−)-[ 11 C]6 also showed the highest accumulation in the striatum compared to the other brain regions of interest (Fig. 2) , including the cerebellum, brain stem, thalamus, cortex, and hippocampus at 5, 30, and 60 min; however, the uptake (%ID/g) ratios of the striatum to cerebellum was only 1.6 at Table 1 . Binding affinities of the final compounds (K i ±SD) [27] or the VAChT ligand (±)-2 K i-VAChT =4.64±0.47 nM, K i-σ1 = 32±10 nM, and K i-σ2 91,500 nM. Blocking agents were administered by i.v. 1 min prior to tracer injection, and uptake was evaluated 30 min p.i. Pretreatment with the YUN-143 (2 mg/kg) did not result in any significant decrease in striatal accumulation of radioactivity in the rats compared to control rats (p90.05). In contrast, pretreatment with VAChT ligand (±)-2 (1 mg/kg) resulted in significant decrease in uptake; the striatal accumulation of the radioactivity in the pretreated rats was reduced by 50 % compared to those without pretreatment (Table 3, 
Ex Vivo Autoradiography Study in the Rat Brain
In order to demonstrate selective accumulation of (−)-[ 11 C]6 also showed the highest uptake in the striatum; however, the ratio was only 1.6-fold at 60 min p.i. %ID/g values (mean ± SD) with n=4 rats per group. p value was determined by using two-tailed paired Student's t test for the striatum uptake in control rats versus rats pretreated with the blocking agent *p90.05; **p=0.0014; ***p=0.025 esterase (AChE) staining on a control rat following a reported procedure [28] confirmed that striatal AChE activity is significantly higher than that in the cortex (Fig. 3) .
Metabolism Study in Rats
The metabolism study of (−)-[ 11 C]2 in rat blood and brain was performed in male SD rats at 5, 20, 40, and 60 min p.i. Both the blood and brain samples were processed, and solvent extracts were injected on a reverse-phase HPLC system. HPLC fractions were collected and the radioactivity was counted on a well counter. Three radioactive peaks were observed in the blood samples with retention times of 3, 6, and 10 min, which correspond to metabolite 1, metabolite 2, and the parent compound (−)-[ 
MicroPET Imaging Studies in the NHP Brain
Preliminary studies of (−)-[ 11 C]2 in rodents have shown that this new PET radiotracer can be potentially used to measure VAChT density in vivo. Therefore, microPET brain imaging studies of (−)-[ 11 C]2 were performed in male cynomolgus macaques (n=3) to assess its potential as an imaging agent to measure VAChT density (Fig. 4) . The microPET studies demonstrated that (−)-[ 11 C]2 readily enters the brain and accumulates in the striatum. Averaged tissue time-activity curves revealed that the results of these studies can be reproduced and that the tracer showed suitable wash-in and wash-out kinetics, in that the radioactivity accumulation reached maximum at around 60 min of tracer injection. The ratio of radioactivity accumulation in the target (striatum) and nontarget (cerebellum) increases gradually and reaches~2-fold at 60 min p.i. This data is in reasonable agreement with the rat studies, which further suggests that this new compound is a promising PET tracer to image VAChT in vivo.
In 2010, Giboureau et al. published a comprehensive review of PET radioligands for imaging VAChT [9] . Although numerous compounds have been developed as potential PET ligands for imaging VAChT, less than ten have been evaluated in NHP or human subjects [25, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Very few are still considered potential candidates for clinical studies due to problems including poor selectivity over σ receptors, rapid metabolism, defluorination, low extraction from the blood, and slow brain kinetics that require a long time to reach pseudoequilibrium [7, 9] . Vesamicol and many analogues which are even more potent inhibitors of VAChT also bind to σ receptors [41] [42] [43] and nonvesicular vesamicol binding protein, and thus lack selectivity [44] . Although (−)-o-[ [45] . In contrast, the regional brain distribution of (−)-[ 18 F]FEOBV was unaffected by pretreatment with haloperidol or (1)-3-PPP in rodents, suggesting it does not bind to dopamine or σ 1 receptors [46] . However, although it has been approved for human studies, (−)-[ 18 F]FEOBV displays very slow striatal equilibrium kinetics in both NHP and human: after 90 min, pseudoequilibrium was not reached in the striatum; striatal accumulation continued to increase for 180 min p.i. in NHP [36] and for 240 min p.i. in normal human subjects [38] . Based on our initial in vitro characterization and the preliminary in vivo evaluation in rodent and NHP reported in this manuscript, we conclude (−)- 
Conclusion
The biodistribution and regional brain uptake of (−)- 11 C]2 revealed good brain penetration, high target to nontarget ratios, and suitable washout kinetics in both rodents and NHPs. Although (−)-6 displayed potent binding towards VAChT and high selectivity over σ 1 receptor in in vitro studies, it did not show selective binding in the rat brain, perhaps related to the somewhat lower affinity for VAChT than that of (−)-[ 11 C]2. Based on our data, we conclude that (−)-[ 11 C]2 is a potential PET tracer for quantifying VAChT in vivo. Future studies will determine if this tracer can be used in clinical studies for imaging VAChT.
